METHODS OF TREATING GLIOBLASTOMA WITH PRODRUGS OF RILUZOLE
Provided is a method of treating glioblastoma in a patient in need of such treatment, comprising administering to the patient a first dosage form comprising a therapeutically active amount of troriluzole or a pharmaceutically acceptable salt thereof.
1 . A method of treating glioblastoma in a patient in need of such treatment, comprising administering to the patient a first dosage form comprising a therapeutically active amount of troriluzole or a pharmaceutically acceptable salt thereof.
2 . The method according to claim 1 , wherein the first dosage form comprises 100 mg of troriluzole or an equivalent amount of a pharmaceutically acceptable salt thereof.
3 . The method according to claim 1 or 2 , wherein the first dosage form comprises 200 mg of troriluzole or an equivalent amount of a pharmaceutically acceptable salt thereof.
4 . The method according to any one of claims 1 to 3 , wherein the first dosage form is administered once a day.
5 . The method according to any one of claims 1 to 4 , wherein the first dosage form is administered twice a day.
6 . The method according to any one of claims 1 to 5 , wherein the duration of treatment is four weeks, and wherein troriluzole or a pharmaceutically acceptable salt thereof is administered in an amount of 100 mg twice a day for the first two weeks and in amount of 200 mg twice a day for the other two weeks.
7 . The method according to any one of claims 1 to 6 , wherein the total amount of troriluzole or a pharmaceutically acceptable salt thereof administered to the patient during the day is 200 mg.
8 . The method according to any one of claims 1 to 7 , wherein the total amount of troriluzole or a pharmaceutically acceptable salt thereof administered to the patient during the day is 300 mg.
9 . The method according to any one of claims 1 to 8 , wherein the total amount of troriluzole or a pharmaceutically acceptable salt thereof administered to the patient during the day is 400 mg.
10 . The method according to any one of claims 1 to 9 , further comprising administering to the patient a second dosage form comprising a therapeutically active amount of temozolomide or a pharmaceutically acceptable salt thereof.
11 . The method according to claim 10 , wherein the second dosage form comprises 75 mg of temozolomide or an equivalent amount of a pharmaceutically acceptable salt thereof.
12 . The method according to claim 10 or 11 , wherein the second dosage form comprises 150 mg of temozolomide or an equivalent amount of a pharmaceutically acceptable salt thereof.
13 . The method according to any one of claims 10 to 12 , wherein the second dosage form is administered once a day.
14 . The method according to any one of claims 10 to 13 , wherein the second dosage form is administered twice a day.
15 . The method according to any one of claims 10 to 14 , wherein the total amount of temozolomide or a pharmaceutically acceptable salt thereof administered to the patient during the day is 75 mg.
16 . The method according to any one of claims 10 to 15 , wherein the total amount of temozolomide or a pharmaceutically acceptable salt thereof administered to the patient during the day is 150 mg.
17 . The method according to any one of claims 1 to 16 , wherein the glioblastoma is newly diagnosed O 6 -methylguanine-DNA-methyltransferase (MGMT) methylated glioblastoma.
18 . The method according to any one of claims 1 to 16 , wherein the glioblastoma is newly diagnosed O 6 -methylguanine-DNA-methyltransferase (MGMT) unmethylated glioblastoma.
19 . The method according to claim 1 , further comprising administering to the patient a third dosage form comprising a therapeutically active amount of lomustine or an equivalent amount of a pharmaceutically acceptable salt thereof.
20 . The method according to claim 19 , wherein the third dosage form comprises 50 mg of lomustine or an equivalent amount of a pharmaceutically acceptable salt thereof.
21 . The method according to claim 19 or 20 , wherein the third dosage form comprises 100 mg of lomustine or an equivalent amount of a pharmaceutically acceptable salt thereof.
22 . The method according to any one of claims 19 to 21 , wherein the third dosage form is administered once a day.
23 . The method according to any one of claims 19 to 22 , wherein the third dosage form is administered twice a day.
24 . The method according to any one of claims 19 to 23 , wherein the total amount of lomustine or a pharmaceutically acceptable salt thereof administered to the patient during the day is 100 mg.
25 . The method according to any one of claims 19 to 24 , wherein the glioblastoma is recurring glioblastoma.
26 . The method according to any one of claims 1 to 25 , further comprising irradiating glioblastoma cells with a therapeutically effective dose of ionizing radiation.
27 . A kit for use in a method of treating a patient afflicted with glioblastoma, the kit comprising:
(a) troriluzole or a pharmaceutically acceptable salt thereof;
(b) temozolomide or a pharmaceutically acceptable salt thereof; and
(b) instructions for administering troriluzole and temozolomide according to the method of any of claims 1 - 26 .
27 . A kit for use in a method of treating a patient afflicted with glioblastoma, the kit comprising:
(a) troriluzole or a pharmaceutically acceptable salt thereof;
(b) lomustine or a pharmaceutically acceptable salt thereof; and
(b) instructions for administering troriluzole and temozolomide according to the method of any of claims 1 - 26 .